Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

Chang-Hee Suh,Dae-Hyun Yoo,Alfredo Berrocal-Kasay,Elia Chalouhi El-Khouri,Francisco Fidenci Cons Molina,Pavel Shesternya,Pedro Miranda,Francisco G. Medina-Rodriguez,Piotr Wiland,Sławomir Jeka,Jose Chavez-Corrales,Thomas Linde,Paweł Hrycaj,Mauricio Abello Banfi,Ihor Hospodarskyy,Janusz Jaworski,Mariusz Piotrowski,Marek Brzosko,Marek Krogulec,Sergii Shevchuk,Armando Calvo,Daina Andersone,Won Park,Seung-Cheol Shim,Sang Joon Lee,Sung-Young Lee

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

2019

Objective The aim of this study was to investigate long-term clinical outcomes of extended treatment with CT-P10, a rituximab biosimilar, compared with rituximab reference products sourced from the USA and the EU (US-RTX and EU-RTX) in rheumatoid arthritis (RA) for up to 48 weeks.

Keywords:

Biosimilar
Pharmacology
Rheumatoid arthritis
Rituximab
Innovator
Internal medicine
Medicine
Randomized controlled trial
Pharmacodynamics
Efficacy
Phases of clinical research
Methotrexate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations